IR@PKUHSC  > 北京大学第三临床医学院  > 肿瘤放疗科
学科主题临床医学
CT-guided permanent I-125 seed interstitial brachytherapy for recurrent retroperitoneal lymph node metastases after external beam radiotherapy
Yao, Lihong1; Jiang, Yuliang1; Jiang, Ping1; Wang, Hao1; Meng, Na1; Qu, Ang1; Tian, Suqing1; Sun, Haitao1; Liu, Chen2; Wang, Junjie1; Zhang, Kaixian3
关键词Re-irradiation I-125 Seed Interstitial Brachytherapy Retroperitoneal Lymph Node Recurrence
刊名BRACHYTHERAPY
2015-09-01
DOI10.1016/j.brachy.2015.05.008
14期:5页:662-669
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Radiology, Nuclear Medicine & Medical Imaging
研究领域[WOS]Oncology ; Radiology, Nuclear Medicine & Medical Imaging
关键词[WOS]STEREOTACTIC BODY RADIOTHERAPY ; GYNECOLOGIC-ONCOLOGY-GROUP ; SQUAMOUS-CELL CARCINOMA ; SALVAGE THERAPY ; PROSTATE-CANCER ; CLINICAL-OUTCOMES ; CERVICAL-CANCER ; IMPLANTATION ; OLIGOMETASTASES ; RECOMMENDATIONS
英文摘要

PURPOSE: To evaluate the feasibility, efficacy, and safety of permanent I-125 seed interstitial brachytherapy reirradiation in patients with retroperitoneal lymph node recurrence under CT guidance.

METHODS AND MATERIALS: Seventeen patients with 19 retroperitoneal lymph node recurrence after external beam radiotherapy underwent CT-guided I-125 seed implant brachytherapy from October 2007 to August 2014. Treatment for all patients was preplanned using a three-dimensional radiation therapy planning system 3-5 days before brachytherapy; dosimetry verification was performed immediately after brachytherapy.

RESULTS: The actuarial D90 (dose delivered to 90% of the target volume) was 100-198 Gy (median, 126.5 Gy). In 9 patients, pain intensity decreased to mild pain 1-3 weeks after brachytherapy. Pain-free survival ranged 2-15 months (median, 5 months; 95% confidence interval [CI]: 0.1, 9.9). The overall response rate was 19 of 19 (100%). The median local control time was 15 months (95% CI: 2.3, 27.7). The 6-, 12-, and 24-month local control rate was 88.0%, 63.2%, and 42.1%, respectively. Twelve patients (70.6%) developed distant metastases and died. Two patients (11.8%) are alive with distant metastases but no evidence of local recurrence. Three patients (17.6%) are alive with no evidence of local recurrence. Median overall survival was 10 months (95% CI: 5.7, 14.3); the 1- and 2-year survival rates were 38.1% and 15.3%, respectively. No major complications related to the procedure occurred during or after brachytherapy.

CONCLUSIONS: Reirradiation with CT-guided permanent I-125 seed interstitial brachytherapy is feasible, safe, and effective as pain relief or salvage treatment for patients with recurrent retroperitoneal lymph nodes. (C) 2015 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

语种英语
WOS记录号WOS:000361080400011
引用统计
被引频次:5[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/54303
专题北京大学第三临床医学院_肿瘤放疗科
北京大学第二临床医学院_肝病科
北京大学第三临床医学院_肿瘤治疗中心
作者单位1.Peking Univ, Hosp 3, Dept Radiat Oncol, Beijing 100191, Peoples R China
2.Peking Univ, Hosp 3, Dept Radiol, Beijing 100191, Peoples R China
3.Tengzhou Cent Peoples Hosp, Dept Oncol, Tengzhou 277599, Shangdong, Peoples R China
推荐引用方式
GB/T 7714
Yao, Lihong,Jiang, Yuliang,Jiang, Ping,et al. CT-guided permanent I-125 seed interstitial brachytherapy for recurrent retroperitoneal lymph node metastases after external beam radiotherapy[J]. BRACHYTHERAPY,2015,14(5):662-669.
APA Yao, Lihong.,Jiang, Yuliang.,Jiang, Ping.,Wang, Hao.,Meng, Na.,...&Zhang, Kaixian.(2015).CT-guided permanent I-125 seed interstitial brachytherapy for recurrent retroperitoneal lymph node metastases after external beam radiotherapy.BRACHYTHERAPY,14(5),662-669.
MLA Yao, Lihong,et al."CT-guided permanent I-125 seed interstitial brachytherapy for recurrent retroperitoneal lymph node metastases after external beam radiotherapy".BRACHYTHERAPY 14.5(2015):662-669.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Yao, Lihong]的文章
[Jiang, Yuliang]的文章
[Jiang, Ping]的文章
百度学术
百度学术中相似的文章
[Yao, Lihong]的文章
[Jiang, Yuliang]的文章
[Jiang, Ping]的文章
必应学术
必应学术中相似的文章
[Yao, Lihong]的文章
[Jiang, Yuliang]的文章
[Jiang, Ping]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。